APA (7th ed.) Citation

Richardson, P. G., Perrot, A., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., . . . Anderson, K. C. (2021). MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM). Clinical lymphoma, myeloma & leukemia, 21, S423. https://doi.org/10.1016/S2152-2650(21)01948-0

Chicago Style (17th ed.) Citation

Richardson, Paul G., et al. "MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) Vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)." Clinical Lymphoma, Myeloma & Leukemia 21 (2021): S423. https://doi.org/10.1016/S2152-2650(21)01948-0.

MLA (9th ed.) Citation

Richardson, Paul G., et al. "MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) Vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)." Clinical Lymphoma, Myeloma & Leukemia, vol. 21, 2021, p. S423, https://doi.org/10.1016/S2152-2650(21)01948-0.